Tessa Romero
Stock Analyst at JP Morgan
(4.24)
# 469
Out of 4,711 analysts
56
Total ratings
42.86%
Success rate
24.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tessa Romero
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UPB Upstream Bio | Initiates: Overweight | $38 | $16.21 | +134.42% | 1 | Nov 5, 2024 | |
| NMRA Neumora Therapeutics | Downgrades: Neutral | $18 → $15 | $10.85 | +38.25% | 4 | Nov 5, 2024 | |
| DYN Dyne Therapeutics | Downgrades: Neutral | $43 → $35 | $23.99 | +45.89% | 4 | Oct 24, 2024 | |
| MCRB Seres Therapeutics | Downgrades: Underweight | n/a | $0.92 | - | 2 | Oct 24, 2024 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $18 → $31 | $44.78 | -30.77% | 5 | Oct 14, 2024 | |
| BHVN Biohaven | Maintains: Overweight | $55 → $68 | $36.26 | +87.53% | 5 | Oct 3, 2024 | |
| CYTK Cytokinetics | Maintains: Overweight | $65 → $71 | $48.87 | +45.28% | 4 | Sep 5, 2024 | |
| EYPT EyePoint Pharmaceuticals | Maintains: Overweight | $32 → $29 | $7.10 | +308.45% | 3 | Aug 13, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Overweight | $30 → $31 | $30.78 | +0.71% | 8 | Aug 12, 2024 | |
| AGIO Agios Pharmaceuticals | Reinstates: Neutral | $46 | $35.42 | +29.87% | 6 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $25 | $16.87 | +48.19% | 6 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $6.28 | +218.47% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $7 | $8.28 | -15.46% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $55 | $38.63 | +42.38% | 2 | Apr 25, 2023 |
Upstream Bio
Nov 5, 2024
Initiates: Overweight
Price Target: $38
Current: $16.21
Upside: +134.42%
Neumora Therapeutics
Nov 5, 2024
Downgrades: Neutral
Price Target: $18 → $15
Current: $10.85
Upside: +38.25%
Dyne Therapeutics
Oct 24, 2024
Downgrades: Neutral
Price Target: $43 → $35
Current: $23.99
Upside: +45.89%
Seres Therapeutics
Oct 24, 2024
Downgrades: Underweight
Price Target: n/a
Current: $0.92
Upside: -
Scholar Rock Holding
Oct 14, 2024
Maintains: Overweight
Price Target: $18 → $31
Current: $44.78
Upside: -30.77%
Biohaven
Oct 3, 2024
Maintains: Overweight
Price Target: $55 → $68
Current: $36.26
Upside: +87.53%
Cytokinetics
Sep 5, 2024
Maintains: Overweight
Price Target: $65 → $71
Current: $48.87
Upside: +45.28%
EyePoint Pharmaceuticals
Aug 13, 2024
Maintains: Overweight
Price Target: $32 → $29
Current: $7.10
Upside: +308.45%
Edgewise Therapeutics
Aug 12, 2024
Maintains: Overweight
Price Target: $30 → $31
Current: $30.78
Upside: +0.71%
Agios Pharmaceuticals
Jun 13, 2024
Reinstates: Neutral
Price Target: $46
Current: $35.42
Upside: +29.87%
Mar 25, 2024
Maintains: Overweight
Price Target: $29 → $25
Current: $16.87
Upside: +48.19%
Nov 28, 2023
Initiates: Overweight
Price Target: $20
Current: $6.28
Upside: +218.47%
Aug 22, 2023
Maintains: Underweight
Price Target: $8 → $7
Current: $8.28
Upside: -15.46%
Apr 25, 2023
Maintains: Overweight
Price Target: $54 → $55
Current: $38.63
Upside: +42.38%